Back to GetFilings.com



Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2005

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from              to             

 

Commission file number: 000-30267

 


 

ORCHID BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware   22-3392819

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

4390 US Route One

Princeton, NJ

  08540
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (609) 750-2200

 


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).    x  Yes    ¨  No

 

As of May 5, 2005, the registrant had 24,464,407 shares of common stock outstanding.

 



Table of Contents

ORCHID BIOSCIENCES, INC. AND SUBSIDIARIES

 

INDEX TO FORM 10-Q

 

         Page

PART I. FINANCIAL INFORMATION
ITEM 1.   Financial Statements (unaudited)    3
    Consolidated Balance Sheets as of March 31, 2005 and December 31, 2004    3
    Consolidated Statements of Operations for the three months ended March 31, 2005 and 2004    4
    Consolidated Statements of Cash Flows for the three months ended March 31, 2005 and 2004    5
    Consolidated Statement of Stockholders’ Equity and Comprehensive Income (Loss) for the three months ended March 31, 2005    6
    Notes to Consolidated Financial Statements    7
ITEM 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations    18
ITEM 3.   Quantitative and Qualitative Disclosures about Market Risk    25
ITEM 4.   Controls and Procedures    26
PART II. OTHER INFORMATION
ITEM 1.   Legal Proceedings    28
ITEM 2.   Unregistered Sales of Equity Securities and Use of Proceeds    28
ITEM 3.   Defaults Upon Senior Securities    28
ITEM 4.   Submission of Matters to a Vote of Security Holders    28
ITEM 5.   Other Information    28
ITEM 6.   Exhibits    29
SIGNATURES    30

 

2


Table of Contents

PART I – FINANCIAL INFORMATION

 

Item 1. FINANCIAL STATEMENTS

 

ORCHID BIOSCIENCES, INC. AND SUBSIDIARIES

 

Consolidated Balance Sheets

(In thousands, except share and per share data)

(unaudited)

 

     March 31,
2005


    December 31,
2004


 
Assets                 

Current assets:

                

Cash and cash equivalents

   $ 24,057     $ 12,112  

Short-term investments

     5,999       18,374  

Restricted cash

     251       251  

Accounts receivable, net

     12,462       14,099  

Inventory

     1,234       1,358  

Prepaids and other current assets

     944       1,296  
    


 


Total current assets

     44,947       47,490  

Fixed assets, net

     9,475       9,977  

Goodwill

     2,761       2,789  

Other intangibles, net

     12,814       13,285  

Restricted cash

     1,736       1,736  

Other assets

     349       345  
    


 


Total assets

   $ 72,082     $ 75,622  
    


 


Liabilities and Stockholders’ Equity                 

Current liabilities:

                

Accounts payable

   $ 2,415     $ 2,603  

Accrued expenses

     7,461       8,504  

Income tax payable

     1,630       1,982  

Current portion of long-term debt

     231       371  

Deferred revenue

     1,047       983  
    


 


Total current liabilities

     12,784       14,443  

Accrued restructuring, less current portion

     1,029       1,029  

Other liabilities

     1,900       1,900  
    


 


Total liabilities

     15,713       17,372  

Commitments and contingencies

                

Stockholders’ equity:

                

Preferred stock, $.001 par value. Authorized 5,000,000 shares; 0 shares issued outstanding as of March 31, 2005 and December 31, 2004, respectively

     —         —    

Series A junior participating preferred stock, $.001 par value. Designated 1,000,000 shares; no shares issued or outstanding

     —         —    

Common stock, $0.001 par value. Authorized 150,000,000 shares; issued and outstanding 24,044,000 and 24,033,000 at March 31, 2005 and December 31, 2004, respectively

     24       24  

Additional paid-in capital

     351,734       351,590  

Accumulated other comprehensive income

     2,577       2,950  

Accumulated deficit

     (297,966 )     (296,314 )
    


 


Total stockholders’ equity

     56,369       58,250  
    


 


Total liabilities and stockholders’ equity

   $ 72,082     $ 75,622  
    


 


 

See accompanying notes to consolidated financial statements.

 

3


Table of Contents

ORCHID BIOSCIENCES, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

Three months ended March 31, 2005 and 2004

(In thousands, except per share data)

(unaudited)

 

     2005

    2004

 

Revenues:

                

Service revenues

   $ 14,489     $ 13,294  

Other revenues

     176       174  
    


 


Total revenues

     14,665       13,468  
    


 


Operating expenses:

                

Cost of service revenues

     9,024       8,343  

Research and development

     397       417  

Marketing and sales

     1,778       1,726  

General and administrative

     4,639       7,534  

Restructuring

     119       1,130  

Amortization of intangible assets

     431       452  
    


 


Total operating expenses

     16,388       19,602  
    


 


Operating loss

     (1,723 )     (6,134 )

Other income (expense):

                

Interest income

     96       9  

Interest expense

     (8 )     (55 )

Other income (expense)

     2       (117 )
    


 


Total other income (expense), net

     90       (163 )
    


 


Loss from continuing operations before income taxes

     (1,633 )     (6,297 )

Income tax expense

     19       135  
    


 


Loss from continuing operations

     (1,652 )     (6,432 )

Discontinued operations:

                

Loss from operations of a business sold

     —         (507 )
    


 


Net loss

     (1,652 )     (6,939 )

Dividends to Series A preferred shareholders

     —         (14 )

Accretion of Series A preferred stock discount

     —         (1,129 )
    


 


Net loss allocable to common stockholders

   $ (1,652 )   $ (8,082 )
    


 


Basic and diluted loss from continuing operations per share allocable to common stockholders

   $ (0.07 )   $ (0.39 )

Basic and diluted loss from discontinued operations per share

     —         (0.02 )
    


 


Basic and diluted net loss per share allocable to common stockholders

   $ (0.07 )   $ (0.41 )
    


 


Shares used in computing basic and diluted net loss per share allocable to common stockholders

     24,040       19,651  

 

See accompanying notes to consolidated financial statements.

 

4


Table of Contents

ORCHID BIOSCIENCES, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

Three months ended March 31, 2005 and 2004

(In thousands)

(unaudited)

 

     2005

    2004

 

Cash flows from operating activities:

                

Loss from continuing operations

   $ (1,652 )   $ (6,432 )

Loss from discontinued operations

     —         (507 )

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

                

Gain on sale of asset

     (14 )     —    

Noncash compensation expense

     104       212  

Depreciation and amortization

     1,377       1,306  

Bad debt expense

     61       23  

Loss of sale of investment

     —         125  

Changes in assets and liabilities:

                

Accounts receivable

     1,576       (1,151 )

Inventory

     124       (357 )

Prepaids and other current assets

     352       400  

Other assets

     (4 )     (166 )

Accounts payable

     (188 )     (2,843 )

Accrued expenses, including restructuring

     (1,041 )     5,923  

Income tax payable

     (352 )     —    

Deferred revenue

     64       (150 )

Other liabilities

     —         458  
    


 


Net cash provided by (used in) operating activities

     407       (3,159 )
    


 


Cash flows from investing activities:

                

Capital expenditures

     (568 )     (432 )

Proceeds from the sale of assets

     14       —    

Maturities of short-term investments

     12,375       —    

Proceeds from the sale of investments

     —         196  
    


 


Net cash provided by (used in) investing activities

     11,821       (236 )
    


 


Cash flows from financing activities:

                

Net proceeds from issuance of common stock

     40       26,209  

Repayment of debt from line of credit

     (140 )     (741 )

Payments of patent obligations

     —         (575 )
    


 


Net cash provided by (used in) financing activities

     (100 )     24,893  
    


 


Effect of foreign currency translation on cash and cash equivalents

     (183 )     281  
    


 


Net increase in cash and cash equivalents

     11,945       21,779  

Cash and cash equivalents at beginning of period

     12,112       9,938  
    


 


Cash and cash equivalents at end of period

   $ 24,057     $ 31,717  
    


 


Supplemental disclosure of noncash financing and investing activities:

                

Dividends to Series A preferred shareholders issued or issuable in common stock

   $ —       $ 14  

Accretion of Series A preferred stock discount resulting from conversions and probable redemption

     —         1,129  

Supplemental disclosure of cash flow information:

                

Cash paid during the period for interest

   $ 9     $ 55  

 

See accompanying notes to consolidated financial statements.

 

5


Table of Contents

ORCHID BIOSCIENCES, INC. AND SUBSIDIARIES

 

Consolidated Statement of Stockholders’ Equity and Comprehensive Loss

Three months ended March 31, 2005

(In thousands)

(unaudited)

 

     Common Stock

   Additional
Paid-in
Capital


   Accumulated
Other
Comprehensive
Income


    Accumulated
Deficit


    Total
Stockholders’
Equity


 
     Number of
Shares


   Amount

         

Balance at January 1, 2005:

   24,033    $ 24    $ 351,590